Mesoblast Ltd's stock surged 5.79% during intraday trading on Friday, marking a significant upward movement for the biotech company.
The sharp rise appears to be driven by the company's optimistic financial outlook, specifically for its product Ryoncil. Mesoblast announced that it sees full-year fiscal 2026 net revenue for Ryoncil ranging between US$110 million and US$120 million, providing investors with a strong growth forecast for the key therapy.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.